Infinity Pharmaceuticals Inc.

369 articles with Infinity Pharmaceuticals Inc.

• Infinity Pharmaceuticals Reports Full Year 2018 Financial Results and Provides Company Update

  3/14/2019

  BMS Clinical Collaboration on MARIO-275, a Randomized Study of IPI-549 and Opdivo® (nivolumab) in I/O Naïve Urothelial Cancer to be Initiated in 2Q19

• Infinity To Initiate MARIO-3, A Phase 2 Multi-Arm Study Evaluating IPI-549 In Front-Line Triple Negative Breast Cancer And Renal Cell Cancer

  3/14/2019

  MARIO-3 Will Evaluate IPI-549 with Tecentriq and Abraxane® in Front-Line Triple Negative Breast Cancer and IPI-549 with Tecentriq and Avastin® in Front-Line Renal Cell Cancer

• Infinity Announces the Date of Its Full Year 2018 Financial Results Conference Call and Webcast

  3/7/2019

  Infinity Pharmaceuticals, Inc. will host a conference call on Thursday, March 14, 2019, at 8:00 a.m. ET to review its full year 2018 financial results and provide an update on the company.

• Infinity Pharmaceuticals Announces Royalty Monetization of COPIKTRA™ for $30 Million Gross Proceeds

  3/6/2019

  Infinity Retains $22.5 Million in Gross Proceeds After Sharing with Takeda

• Infinity Pharmaceuticals To Present At BIO CEO & Investor Conference

  2/4/2019

  Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that Adelene Perkins, Infinity Pharmaceutical's Chief Executive Officer, will present at the BIO CEO & Investor Conference on Monday, February 11, 2019, at 10:00 a.m. EST at The New York Marriott Marquis in New York, NY

• Infinity Pharmaceuticals Provides 2019 Goals and Financial Guidance

  1/7/2019

  IPI-549 Safety and Clinical Activity Support Initiation of Studies in Earlier Lines of Cancer Therapy with Double and Triple Combination Regimens

• Infinity To Present At 37th Annual J.P. Morgan Healthcare Conference

  1/3/2019

  Infinity Pharmaceuticals Inc. (NASDAQ: INFI) will be presenting at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019, at 9:30 a.m. PST (12:30 p.m. EST) in San Francisco, CA.

• 

  Looking into the Crystal Ball: Top Predictions for 2019 by Biopharma Execs

  11/28/2018

  Toward the end of every year, biopharma executives are asked to dust off their crystal balls and predict what the next year might reveal. It’s that time of year again! Find out what execs are saying about M&A, gene therapy, sickle cell, and more.

• Infinity Reports Clinical and Translational Data from Expansion Cohorts of MARIO‑1 Phase 1b Study of IPI-549 in Combination with Opdivo® (nivolumab) at SITC's 33rd Annual Meeting

  11/10/2018

  Clinical Activity and Translational Data from IPI-549 in Monotherapy and in Combination with Opdivo Support On-Mechanism Proof of Concept

• Bristol-Myers Squibb and Infinity Pharmaceuticals Announce a New Clinical Collaboration to Evaluate Opdivo (Nivolumab) in Combination with IPI-549 in Urothelial Cancer

  11/5/2018

  Plans to Initiate MARIO-275, a Randomized, Global Phase 2 Study in 1H'19

• Infinity Pharmaceuticals Provides Company Update and Third Quarter 2018 Financial Results

  11/5/2018

   Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its third quarter 2018 financial results and provided an update on the company and its progress with IPI-549, a first-in-class oral immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase-gamma

• Infinity Announces IPI-549 Late-Breaking Presentation at SITC 33rd Annual Meeting

  11/1/2018

  Combination Expansion Data from the IPI-549 MARIO-1 Phase 1b Study to be Presented

• Infinity Announces the Date of Its Third Quarter 2018 Financial Results Conference Call and Webcast

  10/29/2018

  Infinity Pharmaceuticals, Inc. will host a conference call on Monday, November 5, 2018, at 4:30 p.m. ET to review its third quarter 2018 financial results

• 

  Bay State Life Sciences Companies Offer Strong Incentives Packages to Woo New Hires

  10/12/2018

  For those looking for work, it’s good to know that some positions are in such demand that employers are falling all over themselves to offer hiring incentives. That’s the case with the biotech sector in Massachusetts, as many companies are dangling almost unheard-of benefits as incentives.

• Infinity To Present At BIO Investor Forum

  10/11/2018

  A live webcast of the presentation will be available on the Investors/Media section of Infinity's website at www.infi.com, and will be available for 30 days following the event.

• Infinity Pharmaceuticals Earns $22 Million Payment From Verastem Oncology For FDA Approval Of COPIKTRA™ (duvelisib) And Updates 2018 Financial Guidance

  10/1/2018

  Infinity Pharmaceuticals, Inc. announced today that it earned a $22 million payment from Verastem Oncology under the license agreement between the Company and Verastem for COPIKTRA (duvelisib). 

• /C O R R E C T I O N -- Infinity Pharmaceuticals, Inc./

  9/27/2018

  In the news release, Infinity To Present At Cantor Fitzgerald Global Healthcare Conference, issued 26-Sep-2018 by Infinity Pharmaceuticals, Inc. over PR Newswire, we are advised by the company that the presentation date and time for the Cantor Fitzgerald Global Healthcare Conference have been updated. The complete, corrected release follows:

• Infinity To Present At 2018 Cantor Fitzgerald Global Healthcare Conference

  9/26/2018

  Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at Cantor Fitzgerald's Global Healthcare Conference on Wednesday, October 3, 2018, at 5:10 p.m. ET at the Intercontinental New York Barclay Hotel in New York, NY.

• 

  Verastem Gets FDA Approval for Leukemia Drug, Will Make It Immediately Available to Patients

  9/25/2018

  Shares of Verastem closed out Monday trading on a positive note and continues to climb in the premarket following the greenlight for leukemia drug Copiktra, an inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma.

• Infinity To Present At Three Upcoming Investor Conferences In September

  8/28/2018

  A live webcast of the presentation for each of these conferences, excluding the BioCentury NewsMakers lunch panel discussion, will be available on the Investors/Media section of Infinity's website